Baidu
map

Hum Pathol:在膀胱癌患者中,DUSP2功能丧失预示不良预后

2018-12-02 AlexYang MedSci原创

双特异性磷酸酶2(DUSP2)是I型DUSP家族的一个成员,能够消除细胞分裂激活蛋白酶(MAPKs)的激活,并且在免疫过程、炎症响应和癌症恶化方面中具有重要的作用。目前,是否DUSP2参与了膀胱癌的致病过程仍旧未知。最近,有研究人员阐释了与配对的正常组织和良性上皮细胞相比,DUSP2的表达水平在膀胱癌组织和细胞系中明显下调。另外,DUSP2的表达与病理等级(P=.009)、AJCC阶段(P=.01

双特异性磷酸酶2(DUSP2)是I型DUSP家族的一个成员,能够消除细胞分裂激活蛋白酶(MAPKs)的激活,并且在免疫过程、炎症响应和癌症恶化方面中具有重要的作用。目前,是否DUSP2参与了膀胱癌的致病过程仍旧未知。

最近,有研究人员阐释了与配对的正常组织和良性上皮细胞相比,DUSP2的表达水平在膀胱癌组织和细胞系中明显下调。另外,DUSP2的表达与病理等级(P=.009)、AJCC阶段(P=.017)和癌症基因组图谱(TCGA)群体中的亚型(P=.001)均显著相关;并且在组织芯片(TMA)群体中与TNM阶段(P=.016)相关。Kaplan-Meier分析表明了具有低DUSP2表达的患者具有更短的5年总生存(P=.018 in TCGA; P=.012 in TMA)和更低的无复发生存(P=.008)。Cox回归分析表明了DUSP2表达的减少是2个群体中生存预后的独立高风险因子。

最后,研究人员指出,他们的发现首次表明了DUSP2可以作为膀胱癌的一种恶化和预后生物标记。是否DUSP2在膀胱癌中是一个肿瘤抑制子则需要进一步的研究。

原始出处:

Yin H, He W, Li Y et al. Loss of DUSP2 predicts a poor prognosis in patients with bladder cancer. Hum Pathol. 17 Nov 2018.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2069330, encodeId=bb62206933004, content=<a href='/topic/show?id=8acc634036' target=_blank style='color:#2F92EE;'>#DUSP2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6340, encryptionId=8acc634036, topicName=DUSP2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Wed Nov 13 19:48:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786221, encodeId=fad71e862215b, content=<a href='/topic/show?id=569f13e9045' target=_blank style='color:#2F92EE;'>#Pathol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13790, encryptionId=569f13e9045, topicName=Pathol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Fri Jul 12 10:48:00 CST 2019, time=2019-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336377, encodeId=b1b613363e7aa, content=<a href='/topic/show?id=071820530c5' target=_blank style='color:#2F92EE;'>#不良预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20530, encryptionId=071820530c5, topicName=不良预后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c97a2500111, createdName=thinkibmz_44722594, createdTime=Tue Dec 04 03:48:00 CST 2018, time=2018-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=354325, encodeId=887735432517, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=330b2496122, createdName=1248b886m23暂无昵称, createdTime=Mon Dec 03 12:51:40 CST 2018, time=2018-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=354249, encodeId=6bc0354249ad, content=可以可以, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18e62490830, createdName=1247a70em33暂无昵称, createdTime=Sun Dec 02 15:12:43 CST 2018, time=2018-12-02, status=1, ipAttribution=)]
    2019-11-13 zhaohui6731
  2. [GetPortalCommentsPageByObjectIdResponse(id=2069330, encodeId=bb62206933004, content=<a href='/topic/show?id=8acc634036' target=_blank style='color:#2F92EE;'>#DUSP2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6340, encryptionId=8acc634036, topicName=DUSP2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Wed Nov 13 19:48:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786221, encodeId=fad71e862215b, content=<a href='/topic/show?id=569f13e9045' target=_blank style='color:#2F92EE;'>#Pathol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13790, encryptionId=569f13e9045, topicName=Pathol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Fri Jul 12 10:48:00 CST 2019, time=2019-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336377, encodeId=b1b613363e7aa, content=<a href='/topic/show?id=071820530c5' target=_blank style='color:#2F92EE;'>#不良预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20530, encryptionId=071820530c5, topicName=不良预后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c97a2500111, createdName=thinkibmz_44722594, createdTime=Tue Dec 04 03:48:00 CST 2018, time=2018-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=354325, encodeId=887735432517, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=330b2496122, createdName=1248b886m23暂无昵称, createdTime=Mon Dec 03 12:51:40 CST 2018, time=2018-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=354249, encodeId=6bc0354249ad, content=可以可以, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18e62490830, createdName=1247a70em33暂无昵称, createdTime=Sun Dec 02 15:12:43 CST 2018, time=2018-12-02, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2069330, encodeId=bb62206933004, content=<a href='/topic/show?id=8acc634036' target=_blank style='color:#2F92EE;'>#DUSP2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6340, encryptionId=8acc634036, topicName=DUSP2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Wed Nov 13 19:48:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786221, encodeId=fad71e862215b, content=<a href='/topic/show?id=569f13e9045' target=_blank style='color:#2F92EE;'>#Pathol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13790, encryptionId=569f13e9045, topicName=Pathol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Fri Jul 12 10:48:00 CST 2019, time=2019-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336377, encodeId=b1b613363e7aa, content=<a href='/topic/show?id=071820530c5' target=_blank style='color:#2F92EE;'>#不良预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20530, encryptionId=071820530c5, topicName=不良预后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c97a2500111, createdName=thinkibmz_44722594, createdTime=Tue Dec 04 03:48:00 CST 2018, time=2018-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=354325, encodeId=887735432517, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=330b2496122, createdName=1248b886m23暂无昵称, createdTime=Mon Dec 03 12:51:40 CST 2018, time=2018-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=354249, encodeId=6bc0354249ad, content=可以可以, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18e62490830, createdName=1247a70em33暂无昵称, createdTime=Sun Dec 02 15:12:43 CST 2018, time=2018-12-02, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2069330, encodeId=bb62206933004, content=<a href='/topic/show?id=8acc634036' target=_blank style='color:#2F92EE;'>#DUSP2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6340, encryptionId=8acc634036, topicName=DUSP2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Wed Nov 13 19:48:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786221, encodeId=fad71e862215b, content=<a href='/topic/show?id=569f13e9045' target=_blank style='color:#2F92EE;'>#Pathol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13790, encryptionId=569f13e9045, topicName=Pathol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Fri Jul 12 10:48:00 CST 2019, time=2019-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336377, encodeId=b1b613363e7aa, content=<a href='/topic/show?id=071820530c5' target=_blank style='color:#2F92EE;'>#不良预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20530, encryptionId=071820530c5, topicName=不良预后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c97a2500111, createdName=thinkibmz_44722594, createdTime=Tue Dec 04 03:48:00 CST 2018, time=2018-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=354325, encodeId=887735432517, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=330b2496122, createdName=1248b886m23暂无昵称, createdTime=Mon Dec 03 12:51:40 CST 2018, time=2018-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=354249, encodeId=6bc0354249ad, content=可以可以, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18e62490830, createdName=1247a70em33暂无昵称, createdTime=Sun Dec 02 15:12:43 CST 2018, time=2018-12-02, status=1, ipAttribution=)]
    2018-12-03 1248b886m23暂无昵称

    学习一下

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2069330, encodeId=bb62206933004, content=<a href='/topic/show?id=8acc634036' target=_blank style='color:#2F92EE;'>#DUSP2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6340, encryptionId=8acc634036, topicName=DUSP2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Wed Nov 13 19:48:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786221, encodeId=fad71e862215b, content=<a href='/topic/show?id=569f13e9045' target=_blank style='color:#2F92EE;'>#Pathol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13790, encryptionId=569f13e9045, topicName=Pathol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Fri Jul 12 10:48:00 CST 2019, time=2019-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336377, encodeId=b1b613363e7aa, content=<a href='/topic/show?id=071820530c5' target=_blank style='color:#2F92EE;'>#不良预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20530, encryptionId=071820530c5, topicName=不良预后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c97a2500111, createdName=thinkibmz_44722594, createdTime=Tue Dec 04 03:48:00 CST 2018, time=2018-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=354325, encodeId=887735432517, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=330b2496122, createdName=1248b886m23暂无昵称, createdTime=Mon Dec 03 12:51:40 CST 2018, time=2018-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=354249, encodeId=6bc0354249ad, content=可以可以, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18e62490830, createdName=1247a70em33暂无昵称, createdTime=Sun Dec 02 15:12:43 CST 2018, time=2018-12-02, status=1, ipAttribution=)]
    2018-12-02 1247a70em33暂无昵称

    可以可以

    0

相关资讯

Brit J Cancer:GAS5肿瘤抑制因子lncRNA功能丧失研究

膀胱癌(BlCa)遗传异质性和个性化预后的缺乏导致了患者治疗结果的高度可变性。最近,有研究人员分析了GAS5肿瘤抑制因子lncRNA在改善BlCa预后中的作用。研究人员在一个176名患者组成的筛选群体中对GAS5进行了定量,并将Hedegaard et al.(2016)文章中的476名和TCGA临时性群体(n=413)作为鉴定群体。研究人员还使用复发和恶化对NMIBC进行了生存分析,并利用死亡数

JCO:Pembrolizumab新辅助治疗肌层浸润性膀胱癌

JCO近期发表了一篇文章,研究pembrolizumab作为肌层浸润性膀胱癌(MIBC)患者接受根治性膀胱切除术(RC)之前的新辅助治疗的有效性。

膀胱癌一例!

患者1年前因输尿管癌于我院行左肾、输尿管及膀胱袖状切除术,术后每3月定期复查,未见明显异常。2天前于我院行膀胱镜检示:膀胱占位,无明显尿痛,尿频及肉眼血尿。

Cell Physiol Biochem:在膀胱癌细胞中,miR-1-3p能够促进细胞增殖和入侵

越来越多的证据表明miR-1-3p在恶性肿瘤的恶化过程中具有重要作用。然而,miR-1-3p在膀胱癌中的特异生物学功能仍旧未知。研究人员通过qRT-PCR对膀胱癌组织和细胞系的miR-1-3p水平进行了调查,并利用亚硫酸盐测序PCR进行DNA甲基化分析;利用双荧光素酶报告实验确定了miR-1-3p靶标,并在体内和体外试验中调查了miR-1-3p对膀胱癌细胞的表型影响。研究发现,miR-1-3p在膀

膀胱癌影像一例!

患者1周前于外院查体发现膀胱占位性病变,无尿频、尿急、血尿等症状,不伴发热、腰疼等症状。

Sci Rep:在经历根治性切除术的尿路上皮癌患者中,淋巴血管侵入与淋巴结参与具有相似的预后

最近,有研究人员确定了淋巴血管入侵(LVI)在患有膀胱癌且经历根治性切除术患者中的预后值。研究总共有747名患者经历了根治性切除术治疗。在这些患者中,只有164名没有经历淋巴结切除(LND)。研究人员将患者分成4个组:N0、N1、不具有LND的LVI组和没有LND的无LVI组。研究发现,N1组和LVI组患者具有显著更高的T阶段和等级,并且复发和致死率分别要高出1.5到2倍。在N1组中,与N0组和非

Baidu
map
Baidu
map
Baidu
map